Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Pfizer And BioNTech Pushing Forward With Pivotal Global Study Of COVID-19 Vaccine Candidate

By John F. Heerdink, Jr.

As per reports, U.S. drugmaker Pfizer (PFE) and German biotech BioNTech begin a pivotal global study to assess the performance of its COVID-19 vaccine which it calls BNT162b2. Successful completion of the study will enable the companies to submit the vaccine for regulatory approval by early October, and assist in fulfilling the commitment to supply up to 100 million doses by the end of 2020 and 1.3 billion by the end of 2021. The study will include 30,000 participants and 120 sites globally, including the regions heavily impacted by COVID-19.

“The initiation of the Phase 2/3 trial is a major step forward in our progress toward providing a potential vaccine to help fight the ongoing COVID-19 pandemic,” stated Kathrin Jansen, head of vaccine research and development at Pfizer.

Two doses of the drugmakers’ vaccine are given to patients, helping to boost immunity. The vaccine utilizes chemical messenger RNA to mimic the surface of the coronavirus and teach the immune system to identify and neutralize it. 

Pfizer has signed an agreement to sell 100 million doses of its vaccine to the U.S. government along with an option to buy 500 million more. It is also in talks with other governments, including the European Union, discussing similar deals. Over 150 vaccines are being developed against COVID-19, which has claimed 650,000 lives globally.

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. 

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

Post View Count : 444
(Read Original Story: Pfizer-BioNTech begin late-stage study of lead COVID-19 vaccine candidate in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us